Delivery of CRISPR-Cas9 system for screening and editing RNA binding proteins in cancer

Adv Drug Deliv Rev. 2022 Jan:180:114042. doi: 10.1016/j.addr.2021.114042. Epub 2021 Nov 9.

Abstract

RNA-binding proteins (RBPs) play an important role in RNA metabolism, regulating the stability, localization, and functional dynamics of RNAs. Alternation in the RBP-RNA network has profound implications in cellular physiology, and is related to the development and spread of cancer in certain cases. To regulate the expression of specific genes and their biological activities, various strategies have been applied to target RBPs for cancer treatments, including small-molecule inhibitors, small-interfering RNA, peptides, and aptamers. Recently, the deployment of the CRISPR-Cas9 technology has provided a new platform for RBP screening and regulation. This review summarizes the delivery systems of the CRISPR-Cas9 system and their role in RBP-based cancer therapeutics, including identification of novel RBPs and regulation of cancer-associated RBPs. The efficient delivery of the CRISPR-Cas9 system is important to the profound understanding and clinical transition of RBPs as cancer therapeutic targets.

Keywords: CRISPR screening; CRISPR-Cas9; Cancer; Delivery strategy; RBP editing; RNA; RNA-binding protein.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • CRISPR-Cas Systems*
  • Early Detection of Cancer
  • Genetic Therapy
  • Humans
  • Neoplasms / genetics*
  • RNA-Binding Proteins / genetics*

Substances

  • RNA-Binding Proteins